Anamaris Ibarra
Family · South Miami, FLNPI 1013469766
Payments from drug & device makers
Across 464 payments — averaging $22.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Medtronic$1K
- Novo Nordisk$1K
- Sanofi-aventis U.S. LLC$669
- Mannkind Corporation$632
- Insulet Corporation$597
- plus $5K from 32 others
What the payments were for
- Travel & lodging$6556%
- Food & beverage$9,81693%
- Education$541%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 61 | $1,222 |
| Medtronic | 20 | $1,204 |
| Novo Nordisk | 55 | $1,067 |
| Sanofi-aventis U.S. LLC | 33 | $669 |
| Mannkind Corporation | 30 | $632 |
| Insulet Corporation | 24 | $597 |
| Boehringer Ingelheim | 24 | $466 |
| Bayer | 18 | $417 |
| Amgen(2 entities) | 26 | $416 |
| Abbott | 19 | $414 |
| Lifescan, Inc. | 17 | $333 |
| Tandem Diabetes Care, Inc. | 11 | $326 |
| Zealand Pharma US, Inc. | 8 | $310 |
| Amneal Pharmaceuticals LLC | 15 | $292 |
| AbbVie | 19 | $259 |
| Xeris Pharmaceuticals, Inc. | 12 | $255 |
| Embecta Corp. | 10 | $209 |
| Cequr Corporation | 3 | $192 |
| AstraZeneca | 5 | $186 |
| Amarin Pharma, Inc. | 9 | $162 |
| Novartis | 5 | $104 |
| Kyowa Kirin, Inc. | 3 | $83 |
| Radius Health, Inc. | 4 | $79 |
| Corcept Therapeutics | 4 | $76 |
| Alfasigma USA, Inc. | 3 | $75 |
| BD | 3 | $69 |
| Pfizer | 3 | $65 |
| Alvogen Inc | 3 | $57 |
| IBSA Pharma Inc. | 3 | $50 |
| BTG International Inc. | 2 | $40 |
| Sequel Med Tech, LLC | 2 | $37 |
| Intuity Medical Inc | 2 | $36 |
| Clarus Therapeutics Inc. | 2 | $31 |
| Kowa Pharmaceuticals America, Inc. | 2 | $23 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| GRT US Holding, Inc. | 1 | $21 |
| Vistapharm, Inc. | 1 | $15 |
| Tolmar, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$650
- MyCareLink$170
- Omnipod$144
- CeQur Simplicity$135
- FARXIGA$124
- V-GO DISPOSABLE INSULIN DELIVERY$123
- RYBELSUS$113
How this compares
$10,525 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 552 | $608,371 |
| MounjaroTirzepatide | 483 | $552,821 |
| TrulicityDulaglutide | 161 | $175,476 |
| ProliaDenosumab | 77 | $135,783 |
| RybelsusSemaglutide | 78 | $97,839 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 86 | $90,097 |
| TradjentaLinagliptin | 102 | $89,852 |
| JardianceEmpagliflozin | 74 | $84,069 |
| FarxigaDapagliflozin Propanediol | 95 | $83,734 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 93 | $77,942 |
| VascepaIcosapent Ethyl | 130 | $65,590 |
| Tresiba Flextouch U-200Insulin Degludec | 100 | $63,938 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 81 | $59,142 |
| SynjardyEmpagliflozin/Metformin Hcl | 73 | $57,238 |
| AfrezzaInsulin Regular, Human | 13 | $56,060 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,222 | $734,708677 claims |
| Novo NordiskOzempic, Rybelsus | $1,067 | $706,210630 claims |
| Boehringer IngelheimSynjardy Xr, Tradjenta, Jardiance, Synjardy, Glyxambi | $466 | $404,821433 claims |
| AmgenProlia | $416 | $135,78377 claims |
| AstraZenecaFarxiga | $186 | $83,73495 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $669 | $59,14281 claims |
| Mannkind CorporationAfrezza | $632 | $56,06013 claims |
| BayerKerendia | $417 | $32,59540 claims |
| AbbVieSynthroid | $259 | $24,109208 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.
Other family in South Miami
- Darlena BanasSouth Miami$64K
- Naime Reyno RamosSouth Miami$44K
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.